secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-09-08T22:05:32+00:00
Accession:  0001193125-26-385430
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune's EVO756 Phase 2b fails in atopic dermatitis; AD program halted
------------------------------------------------------------------------

- Phase 2b trial of EVO756 in 121 adults with moderate-to-severe AD missed primary and secondary endpoints at all doses.
- Company will cease EVO756 development for AD; will continue evaluation in migraine prophylaxis.
- EVO301 (IL-18BP fusion protein) becomes lead AD program; Phase 2b planned for mid-2027 after positive Phase 2a data.
- Cash, equivalents, and investments expected to fund operations into 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/0001193125-26-385430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer